🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Ivonescimab

    Summit Therapeutics

    Ivonescimab

    phase 2 small molecule active

    1 trial

  2. Ivonescimab

    Summit Therapeutics

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  3. Ivonescimab

    Summit Therapeutics

    Pleural Mesotheliomas

    phase 2 small molecule active

    1 trial

  4. Ivonescimab

    Summit Therapeutics

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  5. Ivonescimab

    Summit Therapeutics

    Glioblastoma

    phase 2 small molecule active

    1 trial

  6. Ivonescimab

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  7. Ivonescimab

    Summit Therapeutics

    Leiomyosarcoma

    phase 2 small molecule active

    1 trial

  8. Ivonescimab 10 mg/kg

    Summit Therapeutics

    Extensive Stage Lung Small Cell Cancer

    phase 2 small molecule active

    1 trial

  9. Ivonescimab Combined With Chemotherapy

    The First People's Hospital of Lianyungang

    Pretreated Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  10. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  11. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. JMKX000623

    Jemincare

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial

  13. JNJ-42756493, JNJ-42756493, JNJ-42756493

    Janssen-Cilag International N.V.

    Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

    phase 2 small molecule active

    1 trial

  14. JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

    phase 2 small molecule active

    1 trial

  15. JNJ-77242113

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  16. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  17. K0706

    Advanced Accelerator Applications

    Early Parkinson Disease

    phase 2 small molecule terminated

    1 trial

  18. KAI-7535

    Kailera Therapeutics

    Obesity

    phase 2 small molecule active

    2 trials

  19. KB801

    Krystal Biotech Netherlands B.V.

    Neurotrophic Keratitis

    phase 2 mab active

    1 trial

  20. KER-047

    Keros Therapeutics

    Iron Deficiency Anemia

    phase 2 small molecule terminated

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., FLUOROURACIL, CAPECITABINE BIOGARAN 500 mg, comprimé pelliculé, Avastin 25 mg/ml concentrate for solution for infusion., OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE

    phase 2 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan Baxter 50 mg Compresse rivestite

    Istituto Gentili S.r.l.

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MDNA11

    Medicenna Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CISPLATIN , CARBOPLATIN

    Istituto Gentili S.r.l.

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources